SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
Progenics Pharmaceuticals, Inc.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.0013 per share
-----------------------------------------------------------------------------
(Title of Class of Securities)
743187106
----------------------------------
(CUSIP Number)
December 31, 2004
-----------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[X] Rule 13d-1(d)
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
--------------------------------------------------------------------------------
CUSIP No. 743187106
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Paul W. Maddon, M.D., Ph.D.
---------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) |_|
(b) |_|
---------- ---------------------------------------------------------------------
3 SEC USE ONLY
---------- ---------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
--------------------- ----- ----------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,682,177
----- ----------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED None
----- ----------------------------------------------------
BY 7 SOLE DISPOSITIVE POWER
EACH 1,682,177
----- ----------------------------------------------------
REPORTING 8 SHARED DISPOSITIVE POWER
PERSON None
WITH
---------- ---------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,682,177
---------- ---------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|_|
---------- ---------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.7345%
---------- ---------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
---------- ---------------------------------------------------------------------
2
Item 1.
(a) Name of Issuer:
Progenics Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
777 Old Saw Mill River Road
Tarrytown, NY 10591
Item 2.
(a) Name of Person Filing:
Paul W. Maddon, M.D., Ph.D.
(b) Address of Principal Business Office or, if none, Residence:
777 Old Saw Mill River Road
Tarrytown, NY 10591
(c) Citizenship:
United States of America
(d) Title of Class of Securities:
Common Stock, par value $0.0013 per share
(e) CUSIP Number:
743187106
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:
N/A
Item 4. Ownership.
(a) Amount Beneficially Owned:
1,682,177 shares, which includes 1,000 shares held by
reporting person's spouse (the beneficial ownership of which the
reporting person disclaims), and 1,139,775 shares that may be
acquired upon exercise of certain options held by reporting person.
(b) Percent of class:
9.7345%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
1,682,177
3
(ii) Shared power to vote or to direct the vote
None
(iii) Sole power to dispose or to direct the disposition of
1,682,177
(iv) Shared power to dispose or to direct the disposition of
None
Item 5. Ownership of Five Percent or Less of a Class.
N/A
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
N/A
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the Group.
N/A
Item 9. Notice of Dissolution of Group.
N/A
4
Item 10. Certifications.
N/A
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 14, 2005
/s/ PAUL J. MADDON
------------------
Paul J. Maddon, M.D., Ph.D.
5